Great News! JumpCan Pharmaceutical's Pudilan Xiaoyan Oral Liquid Approved as a Protected TCM Variety
On May 15, the National Medical Products Administration approved JumpCan Pharmaceutical's exclusive dosage form product, Pudilan Xiaoyan Oral Liquid, as the first Secondary Protected TCM variety. This achievement not only represents full affirmation of the product's clinical value, quality...
From April 12 to 16, the 2026 Wuzhen Health Conference and the 5th China OTC Conference were grandly held. To promote Chinese pharmaceutical health brand building, enhance the social image and influence of Chinese pharmaceutical health brands, and drive the optimization and upgrading...
Twin Stars Shine! JumpCan Pharmaceutical's Innovative Achievements Take Center Stage at the 2026 Xiding Conference
Recently, the 2026 Xiding Conference was grandly held. As one of China's most influential annual events in the health industry, this edition gathered thousands of national chain terminals, industry elites, and industry partners to discuss industry trends. JumpCan Pharmaceutical showcased two...
Outstanding Achievement! JumpCan's Pudilan Xiaoyan Oral Liquid & Tonpei Both Make the List
From March 24 to 29, the 11st Health Industry Ecological Platform (PHCF) was grandly held in Huzhou, Zhejiang Province. The conference brought together tens of thousands of industry professionals who witnessed the announcement of multiple authoritative industry awards. Among them...
On March 23, JumpCan Pharmaceutical and Pharmplus entered into a deep collaboration for the global Class 1 innovative drug Benvitimod Cream (Zelimei), marking its debut launch in Pharmplus's national chain pharmacies. As a non-hormonal dermatological new drug approved simultaneously...
Recently, the final review results of the Jiangsu Association of Chinese Medicine, the Jiangsu Association of Integrative Medicine, and the Jiangsu Association of Acupuncture-Moxibustion’s TCM Science and Technology Awards for 2024–2025 were publicized. The project "Key Technological Innovation...
JumpCan Pharmaceutical (stock code: 600566) recently announced it has formally signed a collaboration agreement with thederma, granting JumpCan Pharmaceutical exclusive commercialization rights for thederma's Benvitimod Cream (Zelimei) in the People's Republic of China (excluding...
Recently, the Center for Drug Reevaluation, NMPA and the National Center for ADR Monitoring, China issued a commendation to units with outstanding performance in 2025. JumpCan Pharmaceutical Group was awarded the title of "Outstanding Enterprise for Drug, Device and Cosmetic...
JumpCan Pharmaceutical (stock code: 600566) and Akeso (stock code: 9926.HK) have officially signed a collaboration agreement. JumpCan Pharmaceutical obtains exclusive commercialization rights for the Class 1 innovative drug Ebronucimab Injection (Yixining) in the People's Republic of China...
JumpCan Pharmaceutical Partners with PrimeGene to Accelerate Commercialization of Class 1 Innovative Drug Pumecitinib
JumpCan Pharmaceutical Group recently announced that it has entered into a collaboration agreement with PrimeGenX Therapeutics Co., Ltd. (hereinafter "PrimeGene") for the Class 1 innovative JAK1/2 inhibitor Pumecitinib (PG-011) Nasal Spray. Under the terms of the agreement, JumpCan...